secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001935979-24-000073
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024
--------------------------------------------------------------------------------

- Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.
- SCA patients showed 50-70% slower disease progression vs untreated controls, translating to 1.5-2.2 years delay.
- Odds ratio for 2+ point f-SARA worsening at 3 years was 4.1 (95% CI: 2.1, 8.1; p<0.0001) favoring troriluzole.
- Biohaven to submit NDA to FDA in Q4 2024; eligible for priority review given orphan/fast-track designations.
- Company plans US commercialization in 2025 if approved; no FDA-approved treatments currently exist for SCA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000073/0001935979-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000073/bhvn-20240923.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer